Autoinjectors Market - Global Forecast to 2030
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年9月 |
| ページ数 | 383 |
| 図表数 | 602 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.
世界のオートインジェクター市場は、2024 年の 14 億米ドルから 2030 年には 30 億 2000 万米ドルにまで拡大し、13.6% という大幅な CAGR で拡大すると予測されています。オートインジェクター完成製剤市場は、2024 年の 673 億米ドルから 2030 年には 1,342 億 7000 万米ドルにまで急成長し、CAGR 12.2% で成長すると予測されています。
Favorable reimbursement policies in North America and Europe coupled with launch of biosimilars across the globe are some of the factors contributing towards the market growth.
“The manual autoinjectors segment accounted for the largest share in 2023.”
On the basis of technology, the autoinjectors market is further segmented into manual, and automatic. The manual autoinjectors segment dominated the market in 2023, owing to the rise in demand due to rising incidence of conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. Furthermore, cost-effectiveness and expanding new therapeutic applications, is likely to increase their overall market potential for manual autoinjectors in coming years.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market.”
The end user segment in the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. In 2023, the home care settings segment accounted for the largest share owing to increased adoption of autoinjectors at home care settings. Furthermore, cost effectiveness, launch of user friendly autoinjector devices is likely to boost the growth of the home care settings segment. Use of autoinjectors for emergency situations such as anaphylactic reactions is likely to increase demand for autoinjectors in hospitals & clinics further propelling the growth of the market.
“North America: the largest share of the autoinjectors market”
North America dominated the autoinjectors market in 2023 and likely continue dominance during the forecast period. Well-developed healthcare infrastructure, prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis and favourable reimbursement policies in North America are some of the factors influencing the use of autoinjectors subsequently contributing towards market growth. The Asia Pacific autoinjectors market is predicted to grow at the significant CAGR during the forecast period of 2024-2030. The growth of the region is primarily attributed to the presence of large number of pharmaceutical and biopharmaceutical companies and growing number of regulatory apporvals for autoinjectors in the region especially China, India and South Korea.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
- SHL Medical AG (Switzerland)
- Ypsomed AG (Switzerland)
- Becton, Dickinson and Company (BD) (US)
- Recipharm AB (Sweden)
- West Pharmaceutical Services, Inc.(US)
- Phillips-Medisize (US)
- Halozyme, Inc. (US)
- Owen Mumford Ltd. (UK)
- Abbvie Inc. (US)
- Eli Lilly and Company (US)
- Amgen Inc. (US)
- Novo Nordisk A/S (Denmark)
- Jonhson & Jonhson Services Inc. (US)
- Sanofi (France)
- GSK plc (UK)
- Gerresheimer AG (Germany)
- Haselmeier (Germany)
- Oval Medical Technologies Ltd. (UK)
- Kaleo, Inc. (US)
- Solteam Incorporation Co., Ltd. (China)
- Elcam Drug Delivery Devices (Israel)
- Crossject (France)
- Jabil, Inc. (US)
- Congruence Medical Solutions LLC (US)
- Midas Pharma GMBH (Germany)
Research Coverage:
This research report categorizes the autoinjectors market usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity and other therapy areas), Volume (upto 3ml and above 3 ml) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the autoinjectors market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the autoinjectors market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the autoinjector devices and finished formulations market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising prevalence of chronic diseases, increasing regulatory approvals for autoinjectors, high demand for biologics & biosimilars, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (Focus on needle-free drug delivery systems and prevalence of needle phobia ), opportunities (Impending patent expiry of biological molecules, launch of technologically-advanced autoinjectors) and Challenges (Development of autoinjectors for multiple drug viscosities) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market
- Competitive Assessment: SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), and Novo Nordisk A/S (Denmark) among others in the market.
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 INCLUSIONS & EXCLUSIONS 39
1.4 STUDY SCOPE 40
1.4.1 SEGMENTS CONSIDERED 40
1.4.2 YEARS CONSIDERED 41
1.4.3 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 RESEARCH DESIGN 43
2.1.2 SECONDARY DATA 44
2.1.2.1 Objectives of secondary research 44
2.1.3 PRIMARY DATA 44
2.1.3.1 Breakdown of primaries (supply- and demand-side participants) 45
2.1.3.2 Objectives of primary research 45
2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES 46
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS 49
2.3.1 INSIGHTS FROM PRIMARY EXPERTS 51
2.3.2 TOP-DOWN APPROACH 52
2.4 MARKET GROWTH RATE PROJECTIONS 54
2.5 DATA TRIANGULATION 57
2.6 STUDY ASSUMPTIONS 58
2.7 RESEARCH LIMITATIONS 58
2.8 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 66
4.1 AUTOINJECTORS MARKET OVERVIEW 66
4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023) 67
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION AND COUNTRY (2023) 67
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,
2024 VS. 2030 (USD MILLION) 68
4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023 68
4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
5.2.1 DRIVERS 72
5.2.1.1 Rising prevalence of chronic diseases 72
5.2.1.2 Increasing regulatory approvals for autoinjectors 72
5.2.1.3 High demand for biosimilars and biologics 73
5.2.1.4 Growing adoption of self-administered medicines 74
5.2.1.5 Government support and favorable reimbursement policies 74
5.2.2 RESTRAINTS 75
5.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia 75
5.2.3 OPPORTUNITIES 75
5.2.3.1 Impending patent expiry of biological molecules 75
5.2.3.2 Launch of technologically-advanced autoinjectors 77
5.2.4 CHALLENGES 77
5.2.4.1 Development of autoinjectors for multiple drug viscosities 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.4 VALUE CHAIN ANALYSIS 78
5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS) 78
5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS 80
5.5 SUPPLY CHAIN ANALYSIS 82
5.6 ECOSYSTEM ANALYSIS 83
5.6.1 AUTOINJECTOR PROVIDERS 84
5.6.2 END USERS 85
5.6.3 REGULATORY BODIES 86
5.7 REGULATORY ANALYSIS 86
5.7.1 REGULATORY LANDSCAPE 86
5.7.1.1 North America 86
5.7.1.2 Europe 87
5.7.1.3 Asia Pacific 87
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
5.7.2.1 North America 88
5.7.2.2 Europe 88
5.7.2.3 Asia Pacific 89
5.7.2.4 Rest of the World 90
5.8 PORTER’S FIVE FORCES ANALYSIS 90
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 91
5.8.2 BARGAINING POWER OF SUPPLIERS 91
5.8.3 BARGAINING POWER OF BUYERS 92
5.8.4 THREAT OF SUBSTITUTES 92
5.8.5 THREAT OF NEW ENTRANTS 92
5.9 TRADE DATA ANALYSIS 92
5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 93
5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 93
5.10 TECHNOLOGY ANALYSIS 94
5.10.1 KEY TECHNOLOGIES 95
5.10.1.1 Injection mechanism technology 95
5.10.1.2 Electronic and connectivity solutions 95
5.10.2 ADJACENT TECHNOLOGIES 96
5.10.2.1 Wearable drug delivery devices 96
5.10.2.2 Implantable drug delivery systems 96
5.10.3 COMPLEMENTARY TECHNOLOGIES 96
5.10.3.1 Power assistance mechanisms 96
5.10.3.2 Advanced needle technology 97
5.11 PATENT ANALYSIS 97
5.11.1 METHODOLOGY 97
5.11.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 97
5.11.3 INNOVATION AND PATENT APPLICATIONS 98
5.11.4 TOP APPLICANTS FOR PATENTS 98
5.12 INDICATIVE PRICING ANALYSIS 101
5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE 101
5.12.2 AVERAGE SELLING PRICE TREND, BY USAGE 101
5.12.3 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY KEY PLAYER 102
5.12.4 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY REGION 103
5.13 KEY CONFERENCES AND EVENTS, 2024–2025 103
5.14 INVESTMENT AND FUNDING SCENARIO 105
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 106
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
5.15.1.1 Key stakeholders in buying process for autoinjector devices 106
5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations 107
5.15.2 KEY BUYING CRITERIA 108
5.15.2.1 Key buying criteria for autoinjector devices 108
5.15.2.2 Key buying criteria for autoinjector finished formulations 109
5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET 110
6 AUTOINJECTORS MARKET, BY USAGE 111
6.1 INTRODUCTION 112
6.2 DISPOSABLE AUTOINJECTORS 113
6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH 113
6.3 REUSABLE AUTOINJECTORS 118
6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH 118
7 AUTOINJECTORS MARKET, BY TECHNOLOGY 124
7.1 INTRODUCTION 125
7.2 MANUAL AUTOINJECTORS 126
7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH 126
7.3 AUTOMATIC AUTOINJECTORS 131
7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH 131
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 137
8.1 INTRODUCTION 138
8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 138
8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH 138
8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 142
8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET 142
9 AUTOINJECTORS MARKET, BY THERAPY AREA 145
9.1 INTRODUCTION 146
9.2 RHEUMATOID ARTHRITIS 147
9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET 147
9.3 DIABETES 153
9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND 153
9.4 MULTIPLE SCLEROSIS 158
9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH 158
9.5 ANAPHYLAXIS 164
9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH 164
9.6 OBESITY 169
9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH 169
9.7 OTHER THERAPY AREAS 174
10 AUTOINJECTORS MARKET, BY VOLUME 180
10.1 INTRODUCTION 181
10.2 UP TO 3ML VOLUME AUTOINJECTORS 181
10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH 181
10.3 ABOVE 3ML VOLUME AUTOINJECTORS 183
10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET 183
11 AUTOINJECTORS MARKET, BY END USER 184
11.1 INTRODUCTION 185
11.2 HOME CARE SETTINGS 185
11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH 185
11.3 HOSPITALS & CLINICS 188
11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH 188
11.4 AMBULATORY CARE SETTINGS 191
11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH 191
12 AUTOINJECTORS MARKET, BY REGION 194
12.1 INTRODUCTION 195
12.2 NORTH AMERICA 196
12.2.1 US 202
12.2.1.1 US to dominate North American autoinjectors market during forecast period 202
12.2.2 CANADA 208
12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth 208
12.3 EUROPE 213
12.3.1 GERMANY 219
12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth 219
12.3.2 UK 223
12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth 223
12.3.3 FRANCE 227
12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market 227
12.3.4 ITALY 231
12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth 231
12.3.5 SPAIN 234
12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth 234
12.3.6 REST OF EUROPE 238
12.4 ASIA PACIFIC 242
12.4.1 JAPAN 247
12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market 247
12.4.2 CHINA 250
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth 250
12.4.3 INDIA 254
12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth 254
12.4.4 SOUTH KOREA 258
12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market 258
12.4.5 REST OF ASIA PACIFIC 262
12.5 LATIN AMERICA 266
12.5.1 BRAZIL 271
12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth 271
12.5.2 REST OF LATIN AMERICA 274
12.6 MIDDLE EAST & AFRICA 278
12.6.1 GCC COUNTRIES 283
12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market 283
12.6.2 REST OF MIDDLE EAST & AFRICA 287
13 COMPETITIVE LANDSCAPE 291
13.1 INTRODUCTION 291
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 291
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET 291
13.3 REVENUE ANALYSIS 293
13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET 293
13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 294
13.4 MARKET SHARE ANALYSIS 294
13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET 294
13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 296
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 298
13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX:
KEY PLAYERS, 2023 298
13.5.1.1 Stars 298
13.5.1.2 Emerging leaders 298
13.5.1.3 Pervasive players 298
13.5.1.4 Participants 299
13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 300
13.5.2.1 Stars 300
13.5.2.2 Emerging leaders 300
13.5.2.3 Pervasive players 300
13.5.2.4 Participants 300
13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023 302
13.5.3.1 Company footprint 302
13.5.3.2 Region footprint 303
13.5.3.3 Usage footprint 304
13.5.3.4 Volume footprint 306
13.5.3.5 Route of administration footprint 307
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 308
13.6.1 PROGRESSIVE COMPANIES 308
13.6.2 RESPONSIVE COMPANIES 308
13.6.3 DYNAMIC COMPANIES 308
13.6.4 STARTING BLOCKS 308
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 310
13.7 COMPANY VALUATION AND FINANCIAL METRICS 311
13.7.1 FINANCIAL METRICS 311
13.7.2 COMPANY VALUATION 311
13.8 BRAND/PRODUCT COMPARISON 312
13.9 COMPETITIVE SCENARIO 313
13.9.1 PRODUCT LAUNCHES AND APPROVALS 313
13.9.2 DEALS 314
13.9.3 EXPANSIONS 315
13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS 316
13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 317
13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 319
14 COMPANY PROFILES 320
14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET 320
14.1.1 SHL MEDICAL AG 320
14.1.1.1 Business overview 320
14.1.1.2 Products offered 320
14.1.1.3 Recent developments 321
14.1.1.3.1 Product launches 321
14.1.1.3.2 Deals 322
14.1.1.3.3 Expansions 323
14.1.1.4 MnM view 323
14.1.1.4.1 Key strengths 323
14.1.1.4.2 Strategic choices 323
14.1.1.4.3 Weaknesses and competitive threats 323
14.1.2 YPSOMED AG 324
14.1.2.1 Business overview 324
14.1.2.2 Products offered 326
14.1.2.3 Recent developments 327
14.1.2.3.1 Product launches 327
14.1.2.3.2 Deals 327
14.1.2.3.3 Expansions 328
14.1.2.4 MnM view 328
14.1.2.4.1 Key strengths 328
14.1.2.4.2 Strategic choices 328
14.1.2.4.3 Weaknesses and competitive threats 328
14.1.3 BECTON, DICKINSON AND COMPANY (BD) 329
14.1.3.1 Business overview 329
14.1.3.2 Products offered 330
14.1.3.3 Recent developments 331
14.1.3.3.1 Deals 331
14.1.3.3.2 Other developments 331
14.1.3.4 MnM view 331
14.1.3.4.1 Key strengths 331
14.1.3.4.2 Strategic choices 331
14.1.3.4.3 Weaknesses and competitive threats 331
14.1.4 RECIPHARM AB 332
14.1.4.1 Business overview 332
14.1.4.2 Products offered 332
14.1.5 WEST PHARMACEUTICAL SERVICES, INC. 333
14.1.5.1 Business overview 333
14.1.5.2 Products offered 334
14.1.5.3 Recent developments 335
14.1.5.3.1 Expansions 335
14.1.6 PHILLIPS-MEDISIZE 336
14.1.6.1 Business overview 336
14.1.6.2 Products offered 336
14.1.6.3 Recent developments 337
14.1.6.3.1 Product launches 337
14.1.7 HALOZYME, INC. 338
14.1.7.1 Business overview 338
14.1.7.2 Products offered 340
14.1.8 OWEN MUMFORD LTD. 341
14.1.8.1 Business overview 341
14.1.8.2 Products offered 341
14.1.8.3 Recent developments 342
14.1.8.3.1 Product launches 342
14.1.8.3.2 Deals 342
14.1.8.3.3 Expansions 342
14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 343
14.2.1 ABBVIE INC. 343
14.2.1.1 Business overview 343
14.2.1.2 Products offered 344
14.2.1.3 Recent developments 345
14.2.1.3.1 Product launches and approvals 345
14.2.2 ELI LILLY AND COMPANY 346
14.2.2.1 Business overview 346
14.2.2.2 Products offered 348
14.2.2.3 Recent developments 349
14.2.2.3.1 Product approvals 349
14.2.2.3.2 Deals 349
14.2.3 AMGEN INC. 350
14.2.3.1 Business overview 350
14.2.3.2 Products offered 352
14.2.3.3 Recent developments 352
14.2.3.3.1 Product launches 352
14.2.4 NOVO NORDISK A/S 353
14.2.4.1 Business overview 353
14.2.4.2 Products offered 354
14.2.4.3 Recent developments 355
14.2.4.3.1 Product approvals 355
14.2.4.3.2 Deals 355
14.2.4.3.3 Expansions 356
14.2.4.3.4 Other developments 356
14.2.5 JOHNSON & JOHNSON SERVICES, INC. 357
14.2.5.1 Business overview 357
14.2.5.2 Products offered 359
14.2.6 SANOFI 360
14.2.6.1 Business overview 360
14.2.6.2 Products offered 361
14.2.7 GSK PLC 362
14.2.7.1 Business overview 362
14.2.7.2 Products offered 363
14.2.7.3 Recent developments 364
14.2.7.3.1 Product approvals 364
14.3 OTHER PLAYERS 365
14.3.1 GERRESHEIMER AG 365
14.3.2 HASELMEIER 366
14.3.3 OVAL MEDICAL TECHNOLOGIES LTD. 367
14.3.4 KALEO, INC. 368
14.3.5 SOLTEAM INCORPORATION CO., LTD. 369
14.3.6 ELCAM DRUG DELIVERY DEVICES 370
14.3.7 CROSSJECT 371
14.3.8 JABIL INC. 371
14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC 372
14.3.10 MIDAS PHARMA GMBH 372
15 APPENDIX 373
15.1 DISCUSSION GUIDE 373
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 379
15.3 CUSTOMIZATION OPTIONS 381
15.4 RELATED REPORTS 381
15.5 AUTHOR DETAILS 382
LIST OF TABLES
TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS 39
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON AUTOINJECTORS MARKET 56
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE,
2020–2024 73
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS 76
TABLE 5 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS 84
TABLE 6 LIST OF KEY AUTOINJECTOR FINISHED FORMULATION PRODUCT PROVIDERS 85
TABLE 7 LIST OF KEY END USERS 85
TABLE 8 LIST OF KEY REGULATORY BODIES 86
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 13 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 90
TABLE 14 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS),
2021–2023 (USD MILLION) 93
TABLE 15 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS),
2021–2023 (USD MILLION) 93
TABLE 16 LIST OF ADVANTAGES AND DISADVANTAGES OF AUTOINJECTOR TECHNOLOGIES 94
TABLE 17 NUMBER OF PATENTS FILED IN AUTOINJECTORS MARKET, 2014–2024 97
TABLE 18 TOP 10 PATENT OWNERS IN US IN AUTOINJECTORS MARKET, 2014–2024 99
TABLE 19 DETAILED ANALYSIS OF KEY PATENTS IN AUTOINJECTORS MARKET, 2022–2024 100
TABLE 20 INDICATIVE PRICING OF FINISHED FORMULATION PRODUCTS,
BY KEY PLAYER, 2023 102
TABLE 21 INDICATIVE PRICING ANALYSIS OF THERAPY AREAS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION, 2023 103
TABLE 22 AUTOINJECTORS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025 103
TABLE 23 AUTOINJECTOR DEVICES MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 106
TABLE 24 AUTOINJECTOR FINISHED FORMULATIONS MARKET: INFLUENCE OF
KEY STAKEHOLDERS ON BUYING PROCESS 107
TABLE 25 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 112
TABLE 26 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (MILLION UNITS) 112
TABLE 27 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 112
TABLE 28 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (USD MILLION) 113
TABLE 29 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 113
TABLE 30 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 31 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 114
TABLE 32 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 33 LATIN AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 34 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET,
BY REGION, 2022–2030 (USD MILLION) 115
TABLE 35 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 116
TABLE 36 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116
TABLE 37 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 38 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 39 LATIN AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 40 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 118
TABLE 41 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (USD MILLION) 119
TABLE 42 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 119
TABLE 43 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 44 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 120
TABLE 45 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 120
TABLE 46 LATIN AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 47 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 121
TABLE 48 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,
2022–2030 (USD MILLION) 121
TABLE 49 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 50 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 51 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 52 LATIN AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 53 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 123
TABLE 54 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 125
TABLE 55 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (MILLION UNITS) 125
TABLE 56 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 125
TABLE 57 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (USD MILLION) 126
TABLE 58 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 127
TABLE 59 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 60 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 127
TABLE 61 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 128
TABLE 62 LATIN AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 128
TABLE 63 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 128
TABLE 64 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,
2022–2030 (USD MILLION) 129
TABLE 65 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 66 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 67 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 68 LATIN AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 69 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 131
TABLE 70 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 132
TABLE 71 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 132
TABLE 72 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 73 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 133
TABLE 74 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 134
TABLE 75 LATIN AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 76 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET,
BY REGION, 2022–2030 (USD MILLION) 134
TABLE 77 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 135
TABLE 78 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 79 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 80 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 81 LATIN AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 82 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 136
TABLE 83 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 138
TABLE 84 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (MILLION UNITS) 138
TABLE 85 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 86 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (MILLION UNITS) 140
TABLE 87 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 88 EUROPE: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 89 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 90 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 91 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 141
TABLE 92 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 142
TABLE 93 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022–2030 (MILLION UNITS) 143
TABLE 94 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 95 EUROPE: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 96 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 97 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 98 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 144
TABLE 99 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 146
TABLE 100 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (MILLION UNITS) 146
TABLE 101 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 147
TABLE 102 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 148
TABLE 103 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (MILLION UNITS) 148
TABLE 104 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 105 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 106 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 107 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 108 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 150
TABLE 109 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 151
TABLE 110 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 151
TABLE 111 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 112 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 113 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 153
TABLE 114 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 153
TABLE 115 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION,
2022–2030 (USD MILLION) 154
TABLE 116 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION,
2022–2030 (MILLION UNITS) 154
TABLE 117 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 118 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY,
2022–2030 (USD MILLION) 155
TABLE 119 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 120 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 121 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES,
BY REGION, 2022–2030 (USD MILLION) 156
TABLE 122 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022–2030 (USD MILLION) 156
TABLE 123 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 124 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES,
BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 125 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 126 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 158
TABLE 127 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022–2030 (USD MILLION) 158
TABLE 128 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION,
2022–2030 (USD MILLION) 159
TABLE 129 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION,
2022–2030 (MILLION UNITS) 159
TABLE 130 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 131 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2022–2030 (USD MILLION) 160
TABLE 132 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2022–2030 (USD MILLION) 160
TABLE 133 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2022–2030 (USD MILLION) 161
TABLE 134 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022–2030 (USD MILLION) 161
TABLE 135 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS,
BY REGION, 2022–2030 (USD MILLION) 161
TABLE 136 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 162
TABLE 137 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 162
TABLE 138 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 139 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 140 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022–2030 (USD MILLION) 163
TABLE 141 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION,
2022–2030 (USD MILLION) 164
TABLE 142 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION,
2022–2030 (MILLION UNITS) 165
TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS,
BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 144 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 145 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 146 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS,
BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 147 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS,
BY REGION, 2022–2030 (USD MILLION) 166
TABLE 148 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS,
BY REGION, 2022–2030 (USD MILLION) 167
TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 150 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 151 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 152 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 153 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022–2030 (USD MILLION) 168
TABLE 154 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION,
2022–2030 (USD MILLION) 169
TABLE 155 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION,
2022–2030 (MILLION UNITS) 170
TABLE 156 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 157 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY,
2022–2030 (USD MILLION) 170
TABLE 158 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 159 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 160 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY,
BY REGION, 2022–2030 (USD MILLION) 171
TABLE 161 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022–2030 (USD MILLION) 172
TABLE 162 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 172
TABLE 163 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY,
BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 164 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY,
BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 165 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 174
TABLE 166 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022–2030 (USD MILLION) 174
TABLE 167 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 175
TABLE 168 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (MILLION UNITS) 175
TABLE 169 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 175
TABLE 170 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 176
TABLE 171 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2022–2030 (USD MILLION) 176
TABLE 172 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 177
TABLE 173 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 177
TABLE 174 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 177
TABLE 175 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 176 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 177 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 178 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 179
TABLE 179 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 179
TABLE 180 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022–2030 (USD MILLION) 181
TABLE 181 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022–2030 (MILLION UNITS) 181
TABLE 182 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (USD MILLION) 182
TABLE 183 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 182
TABLE 184 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (USD MILLION) 183
TABLE 185 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION,
2022–2030 (MILLION UNITS) 183
TABLE 186 AUTOINJECTOR DEVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 185
TABLE 187 AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION,
2022–2030 (USD MILLION) 186
TABLE 188 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 186
TABLE 189 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 187
TABLE 190 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 187
TABLE 191 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 188
TABLE 192 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 188
TABLE 193 AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION,
2022–2030 (USD MILLION) 189
TABLE 194 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 195 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 196 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 190
TABLE 197 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 190
TABLE 198 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION) 190
TABLE 199 AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 191
TABLE 200 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 192
TABLE 201 EUROPE: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 192
TABLE 202 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 192
TABLE 203 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 193
TABLE 204 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 193
TABLE 205 AUTOINJECTOR DEVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 195
TABLE 206 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,
2022–2030 (USD MILLION) 195
TABLE 207 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 198
TABLE 208 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 198
TABLE 209 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 198
TABLE 210 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 199
TABLE 211 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 199
TABLE 212 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2022–2030 (USD MILLION) 199
TABLE 213 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 200
TABLE 214 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 200
TABLE 215 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 200
TABLE 216 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 201
TABLE 217 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 201
TABLE 218 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 201
TABLE 219 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022–2030 (USD MILLION) 202
TABLE 220 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 202
TABLE 221 AUTOINJECTORS APPROVED BY US FDA, 2018–2024 204
TABLE 222 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 204
TABLE 223 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 205
TABLE 224 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 205
TABLE 225 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 205
TABLE 226 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 206
TABLE 227 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 206
TABLE 228 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 206
TABLE 229 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 207
TABLE 230 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 207
TABLE 231 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 208
TABLE 232 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 209
TABLE 233 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 209
TABLE 234 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 209
TABLE 235 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 210
TABLE 236 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 210
TABLE 237 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 210
TABLE 238 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 211
TABLE 239 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 211
TABLE 240 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 211
TABLE 241 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 212
TABLE 242 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 215
TABLE 243 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 215
TABLE 244 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 215
TABLE 245 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 216
TABLE 246 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 216
TABLE 247 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2022–2030 (USD MILLION) 216
TABLE 248 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 217
TABLE 249 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 217
TABLE 250 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 217
TABLE 251 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 218
TABLE 252 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 218
TABLE 253 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 218
TABLE 254 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME,
2022–2030 (USD MILLION) 219
TABLE 255 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 219
TABLE 256 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 220
TABLE 257 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 220
TABLE 258 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 221
TABLE 259 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 221
TABLE 260 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 221
TABLE 261 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 222
TABLE 262 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 222
TABLE 263 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 222
TABLE 264 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 223
TABLE 265 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 223
TABLE 266 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 224
TABLE 267 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 224
TABLE 268 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 224
TABLE 269 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 225
TABLE 270 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 225
TABLE 271 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 225
TABLE 272 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 226
TABLE 273 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 226
TABLE 274 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 226
TABLE 275 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 227
TABLE 276 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 227
TABLE 277 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 228
TABLE 278 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 228
TABLE 279 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 228
TABLE 280 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 229
TABLE 281 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 229
TABLE 282 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 229
TABLE 283 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 230
TABLE 284 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 230
TABLE 285 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 230
TABLE 286 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 231
TABLE 287 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 231
TABLE 288 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 232
TABLE 289 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 232
TABLE 290 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 232
TABLE 291 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 233
TABLE 292 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 233
TABLE 293 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 233
TABLE 294 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 234
TABLE 295 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 234
TABLE 296 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 235
TABLE 297 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 235
TABLE 298 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 235
TABLE 299 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 236
TABLE 300 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 236
TABLE 301 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 236
TABLE 302 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 237
TABLE 303 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 237
TABLE 304 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 237
TABLE 305 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 238
TABLE 306 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 238
TABLE 307 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 239
TABLE 308 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 239
TABLE 309 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 239
TABLE 310 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 240
TABLE 311 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 240
TABLE 312 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 240
TABLE 313 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 241
TABLE 314 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY THERAPY AREA, 2022–2030 (USD MILLION) 241
TABLE 315 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 241
TABLE 316 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 242
TABLE 317 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 242
TABLE 318 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 243
TABLE 319 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 243
TABLE 320 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 243
TABLE 321 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2022–2030 (USD MILLION) 244
TABLE 322 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 244
TABLE 323 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 244
TABLE 324 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 245
TABLE 325 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 245
TABLE 326 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 245
TABLE 327 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 246
TABLE 328 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022–2030 (USD MILLION) 246
TABLE 329 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 246
TABLE 330 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 247
TABLE 331 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 247
TABLE 332 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 248
TABLE 333 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 248
TABLE 334 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 248
TABLE 335 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 249
TABLE 336 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 249
TABLE 337 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 249
TABLE 338 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 250
TABLE 339 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 250
TABLE 340 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 251
TABLE 341 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 251
TABLE 342 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 252
TABLE 343 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 252
TABLE 344 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 252
TABLE 345 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 253
TABLE 346 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 253
TABLE 347 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 253
TABLE 348 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 254
TABLE 349 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 254
TABLE 350 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 255
TABLE 351 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 255
TABLE 352 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 255
TABLE 353 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 256
TABLE 354 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 256
TABLE 355 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 256
TABLE 356 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 257
TABLE 357 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 257
TABLE 358 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 257
TABLE 359 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 258
TABLE 360 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 258
TABLE 361 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 259
TABLE 362 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 259
TABLE 363 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 259
TABLE 364 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 260
TABLE 365 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 260
TABLE 366 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 260
TABLE 367 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 261
TABLE 368 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 261
TABLE 369 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 261
TABLE 370 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 262
TABLE 371 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 262
TABLE 372 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 263
TABLE 373 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 263
TABLE 374 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 263
TABLE 375 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY USAGE, 2022–2030 (USD MILLION) 264
TABLE 376 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 264
TABLE 377 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 264
TABLE 378 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY THERAPY AREA, 2022–2030 (USD MILLION) 265
TABLE 379 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 265
TABLE 380 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 266
TABLE 381 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 266
TABLE 382 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 267
TABLE 383 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 267
TABLE 384 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 267
TABLE 385 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2022–2030 (USD MILLION) 268
TABLE 386 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 268
TABLE 387 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 268
TABLE 388 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 269
TABLE 389 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 269
TABLE 390 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 269
TABLE 391 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 270
TABLE 392 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022–2030 (USD MILLION) 270
TABLE 393 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 270
TABLE 394 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 271
TABLE 395 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 271
TABLE 396 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2030 (USD MILLION) 272
TABLE 397 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 272
TABLE 398 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 272
TABLE 399 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2022–2030 (USD MILLION) 273
TABLE 400 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 273
TABLE 401 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 273
TABLE 402 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 274
TABLE 403 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2022–2030 (USD MILLION) 274
TABLE 404 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 275
TABLE 405 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 275
TABLE 406 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 275
TABLE 407 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 276
TABLE 408 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 276
TABLE 409 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY USAGE, 2022–2030 (USD MILLION) 276
TABLE 410 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 277
TABLE 411 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 277
TABLE 412 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY THERAPY AREA, 2022–2030 (USD MILLION) 277
TABLE 413 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 278
TABLE 414 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 279
TABLE 415 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 279
TABLE 416 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 279
TABLE 417 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 280
TABLE 418 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 280
TABLE 419 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2022–2030 (USD MILLION) 280
TABLE 420 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 281
TABLE 421 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 281
TABLE 422 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY USAGE, 2022–2030 (USD MILLION) 281
TABLE 423 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 282
TABLE 424 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 282
TABLE 425 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY THERAPY AREA, 2022–2030 (USD MILLION) 282
TABLE 426 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY VOLUME, 2022–2030 (USD MILLION) 283
TABLE 427 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY END USER, 2022–2030 (USD MILLION) 283
TABLE 428 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2022–2030 (USD MILLION) 284
TABLE 429 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY,
2022–2030 (USD MILLION) 284
TABLE 430 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 284
TABLE 431 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA,
2022–2030 (USD MILLION) 285
TABLE 432 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER,
2022–2030 (USD MILLION) 285
TABLE 433 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 285
TABLE 434 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 286
TABLE 435 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 286
TABLE 436 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 286
TABLE 437 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 287
TABLE 438 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 287
TABLE 439 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY TECHNOLOGY, 2022–2030 (USD MILLION) 288
TABLE 440 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 288
TABLE 441 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 288
TABLE 442 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY END USER, 2022–2030 (USD MILLION) 289
TABLE 443 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022–2030 (USD MILLION) 289
TABLE 444 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 289
TABLE 445 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 290
TABLE 446 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 290
TABLE 447 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022–2030 (USD MILLION) 290
TABLE 448 OVERVIEW OF STRATEGIES DEPLOYED BY KEY AUTOINJECTOR DEVICE MANUFACTURING COMPANIES 291
TABLE 449 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION 295
TABLE 450 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION 297
TABLE 451 AUTOINJECTOR DEVICES MARKET: REGION FOOTPRINT 303
TABLE 452 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGION FOOTPRINT 304
TABLE 453 AUTOINJECTOR DEVICES MARKET: USAGE FOOTPRINT 304
TABLE 454 AUTOINJECTOR FINISHED FORMULATIONS MARKET: USAGE FOOTPRINT 305
TABLE 455 AUTOINJECTOR DEVICES MARKET: VOLUME FOOTPRINT 306
TABLE 456 AUTOINJECTOR DEVICES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 307
TABLE 457 AUTOINJECTOR FINISHED FORMULATIONS MARKET: ROUTE OF
ADMINISTRATION FOOTPRINT 308
TABLE 458 AUTOINJECTORS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 310
TABLE 459 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUP/SME PLAYERS 310
TABLE 460 AUTOINJECTORS MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–JULY 2024 313
TABLE 461 AUTOINJECTORS MARKET: DEALS, JANUARY 2021–JULY 2024 314
TABLE 462 AUTOINJECTORS MARKET: EXPANSIONS, JANUARY 2021–JULY 2024 315
TABLE 463 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS 316
TABLE 464 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS 317
TABLE 465 FORMULATION AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS 318
TABLE 466 SHL MEDICAL AG: COMPANY OVERVIEW 320
TABLE 467 SHL MEDICAL AG: PRODUCTS OFFERED 320
TABLE 468 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 321
TABLE 469 SHL MEDICAL AG: DEALS, JANUARY 2021–JULY 2024 322
TABLE 470 SHL MEDICAL AG: EXPANSIONS, JANUARY 2021–JULY 2024 323
TABLE 471 YPSOMED AG: COMPANY OVERVIEW 324
TABLE 472 YPSOMED AG: PRODUCTS OFFERED 326
TABLE 473 YPSOMED AG: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 327
TABLE 474 YPSOMED AG: DEALS, JANUARY 2021–JULY 2024 327
TABLE 475 YPSOMED AG: EXPANSIONS, JANUARY 2021–JULY 2024 328
TABLE 476 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 329
TABLE 477 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 330
TABLE 478 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2021–JULY 2024 331
TABLE 479 BECTON, DICKINSON AND COMPANY (BD): OTHER DEVELOPMENTS,
JANUARY 2021–JULY 2024 331
TABLE 480 RECIPHARM AB: COMPANY OVERVIEW 332
TABLE 481 RECIPHARM AB: PRODUCTS OFFERED 332
TABLE 482 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 333
TABLE 483 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 334
TABLE 484 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,
JANUARY 2021–JULY 2024 335
TABLE 485 PHILLIPS-MEDISIZE: COMPANY OVERVIEW 336
TABLE 486 PHILLIPS-MEDISIZE: PRODUCTS OFFERED 336
TABLE 487 PHILLIPS-MEDISIZE: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 337
TABLE 488 HALOZYME, INC.: COMPANY OVERVIEW 338
TABLE 489 HALOZYME, INC.: PRODUCTS OFFERED 340
TABLE 490 OWEN MUMFORD LTD.: COMPANY OVERVIEW 341
TABLE 491 OWEN MUMFORD LTD.: PRODUCTS OFFERED 341
TABLE 492 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 342
TABLE 493 OWEN MUMFORD LTD.: DEALS, JANUARY 2021–JULY 2024 342
TABLE 494 OWEN MUMFORD LTD.: EXPANSIONS, JANUARY 2021–JULY 2024 342
TABLE 495 ABBVIE INC.: COMPANY OVERVIEW 343
TABLE 496 ABBVIE INC.: PRODUCTS OFFERED 344
TABLE 497 ABBVIE INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2024 345
TABLE 498 ELI LILLY AND COMPANY: COMPANY OVERVIEW 346
TABLE 499 ELI LILLY AND COMPANY: PRODUCTS OFFERED 348
TABLE 500 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–JULY 2024 349
TABLE 501 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–JULY 2024 349
TABLE 502 AMGEN INC.: COMPANY OVERVIEW 350
TABLE 503 AMGEN INC.: PRODUCTS OFFERED 352
TABLE 504 AMGEN INC.: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024 352
TABLE 505 NOVO NORDISK A/S: COMPANY OVERVIEW 353
TABLE 506 NOVO NORDISK A/S: PRODUCTS OFFERED 354
TABLE 507 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–JULY 2024 355
TABLE 508 NOVO NORDISK A/S: DEALS, JANUARY 2021–JULY 2024 355
TABLE 509 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–JULY 2024 356
TABLE 510 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2024 356
TABLE 511 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 357
TABLE 512 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 359
TABLE 513 SANOFI: COMPANY OVERVIEW 360
TABLE 514 SANOFI: PRODUCTS OFFERED 361
TABLE 515 GSK PLC: COMPANY OVERVIEW 362
TABLE 516 GSK PLC: PRODUCTS OFFERED 363
TABLE 517 GSK PLC: PRODUCT APPROVALS, JANUARY 2021–JULY 2024 364
TABLE 518 GERRESHEIMER AG: COMPANY OVERVIEW 365
TABLE 519 HASELMEIER: COMPANY OVERVIEW 366
TABLE 520 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW 367
TABLE 521 KALEO, INC.: COMPANY OVERVIEW 368
TABLE 522 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW 369
TABLE 523 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW 370
TABLE 524 CROSSJECT: COMPANY OVERVIEW 371
TABLE 525 JABIL INC.: COMPANY OVERVIEW 371
TABLE 526 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW 372
TABLE 527 MIDAS PHARMA GMBH: COMPANY OVERVIEW 372
LIST OF FIGURES
FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED 40
FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED 41
FIGURE 3 AUTOINJECTORS MARKET: RESEARCH DESIGN 43
FIGURE 4 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 45
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 46
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES:
REVENUE SHARE ANALYSIS 47
FIGURE 7 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2023) 47
FIGURE 8 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 49
FIGURE 9 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: REVENUE SHARE ANALYSIS 50
FIGURE 10 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2023) 50
FIGURE 11 AUTOINJECTORS MARKET: MARKET VALIDATION FROM PRIMARY EXPERTS 51
FIGURE 12 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 52
FIGURE 13 AUTOINJECTOR DEVICES MARKET SIZE ESTIMATION 53
FIGURE 14 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2024–2030) 55
FIGURE 15 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
(2024–2030) 55
FIGURE 16 DATA TRIANGULATION METHODOLOGY 57
FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (USD MILLION) 60
FIGURE 18 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (MILLION UNITS) 61
FIGURE 19 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,
2024 VS. 2030 (USD BILLION) 61
FIGURE 20 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024 VS. 2030 (USD MILLION) 62
FIGURE 21 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD BILLION) 62
FIGURE 22 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 63
FIGURE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,
2024 VS. 2030 (USD BILLION) 63
FIGURE 24 AUTOINJECTOR DEVICES MARKET: REGIONAL SNAPSHOT 64
FIGURE 25 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGIONAL SNAPSHOT 65
FIGURE 26 INCREASING REGULATORY APPROVALS FOR FINISHED FORMULATION DRUGS TO PROPEL MARKET GROWTH 66
FIGURE 27 US AND DISPOSABLE AUTOINJECTORS DOMINATED MARKET IN 2023 67
FIGURE 28 US AND SUBCUTANEOUS ROUTE OF ADMINISTRATION COMMANDED LARGER MARKET SHARE IN 2023 67
FIGURE 29 RHEUMATOID ARTHRITIS TO DOMINATE MARKET DURING FORECAST PERIOD 68
FIGURE 30 MANUAL AUTOINJECTORS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 68
FIGURE 31 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 69
FIGURE 32 ASIA PACIFIC TO COMMAND HIGHEST CAGR DURING STUDY PERIOD 70
FIGURE 33 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71
FIGURE 34 REVENUE SHIFT AND POCKETS FOR AUTOINJECTOR PROVIDERS 78
FIGURE 35 AUTOINJECTOR DEVICES MARKET: VALUE CHAIN ANALYSIS 79
FIGURE 36 AUTOINJECTOR FINISHED FORMULATIONS MARKET: VALUE CHAIN ANALYSIS 81
FIGURE 37 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS 83
FIGURE 38 AUTOINJECTORS MARKET: ECOSYSTEM MAP 83
FIGURE 39 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 91
FIGURE 40 TOTAL NUMBER OF PATENTS GRANTED, 2014–2023 98
FIGURE 41 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT
APPLICATIONS, 2014–2024 98
FIGURE 42 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2024 99
FIGURE 43 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE (2021–2023) 101
FIGURE 44 AVERAGE SELLING PRICE TREND, BY USAGE (2023) 101
FIGURE 45 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL COMPANIES (AUTOINJECTOR DEVICES) 106
FIGURE 46 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS
(AUTOINJECTOR FINISHED FORMULATIONS) 107
FIGURE 47 KEY BUYING CRITERIA FOR AUTOINJECTOR DEVICES AMONG END USERS 108
FIGURE 48 KEY BUYING CRITERIA FOR AUTOINJECTOR FINISHED FORMULATIONS
AMONG END USERS 109
FIGURE 49 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2023) 196
FIGURE 50 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT (2023) 197
FIGURE 51 EUROPE: AUTOINJECTOR DEVICES MARKET SNAPSHOT 213
FIGURE 52 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT 214
FIGURE 53 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET
(2021–2023) 293
FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2021–2023) 294
FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2023) 295
FIGURE 56 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2023) 297
FIGURE 57 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 299
FIGURE 58 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 301
FIGURE 59 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT 302
FIGURE 60 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY FOOTPRINT 303
FIGURE 61 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 309
FIGURE 62 EV/EBITDA OF KEY VENDORS 311
FIGURE 63 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 311
FIGURE 64 AUTOINJECTOR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 312
FIGURE 65 YPSOMED AG: COMPANY SNAPSHOT (2023) 325
FIGURE 66 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2023) 330
FIGURE 67 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2023) 334
FIGURE 68 HALOZYME, INC.: COMPANY SNAPSHOT (2023) 339
FIGURE 69 ABBVIE INC.: COMPANY SNAPSHOT (2023) 344
FIGURE 70 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023) 347
FIGURE 71 AMGEN INC.: COMPANY SNAPSHOT (2023) 351
FIGURE 72 NOVO NORDISK A/S: COMPANY SNAPSHOT (2023) 354
FIGURE 73 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023) 358
FIGURE 74 SANOFI: COMPANY SNAPSHOT (2023) 361
FIGURE 75 GSK PLC: COMPANY SNAPSHOT (2023) 363
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11